Submitted

To

By

Prof. Shewta JainProf. Ankita Jain

Shivendra Singh PariharM.B.A. 2nd Sem. A

Market Report on Anti-biotic Industry

Pioneer Institute Of Professional StudiesIndore (M.P.)

Contents:Contents:IntroductionMarket CharacterizationMarket PlayersMarketing strategiesMarket shareKey Successful FactorLatest Development of ProductReference

A substance produce by bacteria or fungi that destroy or prevents the growth of other bacteria and fungi.

The first anti-biotic was penicillin & some other anti-biotic are cephalosporins, macrolides, quinolines, aminoglycoside etc.

The anti-biotic is one of the drug which are most widely prescribed by the doctor.

The global market for anti-biotic is reached US$ 40.3 billions upto 2010.

The anti-biotic market in India to become a US$686 million in 2010.

There are 197 companies in the anti-biotic industry.

The major player in the market of anti-biotic industry is GSK, Ranbaxy, Alkem, FDC pfizer.

Introduction

Anti-biotic Market characterization

Approximately 52-55 million anti-biotic are sold annually.

Anti-biotic industry invest 20-25 million a year on promotion.

The Indian market size of 50,000 crore.

Most of the doctor prescribed the anti-biotic drugs to both human and animal.

There are 1000 anti-biotic currently available in Indian Market.

Anti-biotic segment has high percentage of revenue for major pharmaceutical company in India.

The cephalosporin market in India is estimated at around 1000 crore for the 2011.

Market Players

GlaxoSmithKline

It is one of the oldest pharmaceutical company and established in 1929 in India.

It has 2 manufacturing unit in India Nasik & Thane and clinical development centre in Bangalore .

The share of the GSK in anti-biotic is 17%.

Augmentin anti-biotic ranked first cumulative sale of 27.4 crore in quarter from jan to march in 2010.

Their main strength is focused on R & D capabilities.

Opportunity are in new product launches and approval.

Ranbaxy

It is one of the largest pharmaceutical company, it is incorporated in 1961 and its antibiotic product are in 125 company including India.

The headquarter of Ranbaxy is in Gurgaon & Haryana.

Its global sale US$ 1300 million and in India 300 million in anti-biotic.

The mox antibiotic ranked second in India with cumulative sale of 26.6 crore in quarter from January to March.

There main strength is global manufacturing and supply network.

Opportunity are grow in emerging market.

It is one of the company who invested more in promotional as compare to rest of the company in anti-biotic.

FDCIt is established in 1936, it is one of the company in India to usher in the BFS technology offering a sterile quality assured product in anti-biotic.

FDC is one of the company who are winner of quality excellence award for consecutive five years by the Indian drug manufacturing association and they also receive the national award for R & D effort in industry by the government of India.

Anti-biotic Zifi ranked 3rd in antibiotic with cumulative sale of 23.6 crore.

There main strength in wide product range in anti-biotic and in R & D capability and manufacturing capacity.

Opportunity of FDC in new product launches and approval.

The total revenue in 2010 of anti-biotic is about 19%.

Alkem

Alkem laboratories found in 1979. they are one of the largest manufacturing production plant in mandva Gujarat.

The taxem anti-biotic ranked 4th with cumulative sale 22 crore in quarter from jan to march.

Strength of alkem is sale & marketing and along with its expertise in brand building.

The opportunity of alkem that the can explore and exploit are sized up and growth potential assessed in the profile.

The product of company is price slightly higher then the other company.

Pfizer

Pfizer was founded in 1848 and in India 1950, its headquarter in India is in Mumbai and their manufacturing unit are in Thane.

Pfizer become the first company to manufacture penicillin in large volume.

It has invested 15.75 million in clinical research in India.

The anti-biotic bacitracin ranked 5th in India and cumulative sale 21 crore in quarter jan to march.

Pfizer R & D mainly focused on anti-biotic drug.

Opportunity for global growth pfizer highlighted new commercial model that take advantage of its existing medicine and its global R & D manufacturing sale and marketing.

Marketing Strategies

Strategy of GSK is to increase growth and reduce risk and improve GSK long term financial performance.

Strategy of Ranbaxy is grow a diversified global business.

Strategy of FDC is deliver more product of value.

The growth strategy of pfizer include optimizing the company patent protected portfolio.

Market Share

Key success factor in the market

High profit after launching the product because of strong need of people.

Strong product development and regulatory skill.

Marketing sales and distributor.

Quality of anti-biotic drugs are the main key of success.

Patent is the another factor by which they can come with a unique selling proposition and they isolate from competition.

Latest development of Product

GSK exercise on ANCOR new anti-biotic for treatment of gram negative infection .

Ranbaxy develop a new anti-biotic amikin.

FDC launches a new anti-biotic bleph-10 in 2010.

Alkem developed trimpex anti-biotic for the treatment of gram positive infection.

Pfizer launches a new anti-biotic Doribax in dec 2010.

India has launched a mission to screen and developed anti-biotic molecule to tap the over $25 billion, global anti-biotic market the total cost of the project is Rs. 248.6 million of which the biotechnology department contribution is 179.8 million.

Reference

www.google.com

www.ranbaxy.com

www.pfizer.co.uk

www.alkemlabs.com

www.fdcindia.com

www.gsk.com